Figure 1

Subject disposition. The number of subjects who were screened, randomized and received at least 1 dose of study drug (safety population), and completed the study is shown. ^aDoes not include subjects (n = 92) who completed the 3-year core study and did not enter the extension study. ^bDefined as occurrence of new vertebral fracture or ≥7% decrease in BMD of the lumbar spine or hip at any time during the study (P < 0.01 among treatment groups, Chi-square test).